Use of nifurtimox for treating giardiasis

Abstract

The present invention relates to the use of nifurtimox for the treatment of giardiasis, particularly in dogs and cats.

Description

technical field [0001] The present invention relates to the use of nifurtimox for the treatment of Giardiose, especially in dogs and cats. Background technique [0002] The efficacy of nitroheterocyclic compounds against protozoan diseases is known (1). [0003] Protozoa include monokaryotic organisms whose basic structure is eukaryotic cells. However, a more detailed taxonomy reveals large differences in origin, morphology, and biochemical metabolism among lines, classes, genera, and species. This is why, depending on their target and active ingredient, chemicals generally do not act equally well on all protozoa, but only on specific groups of protozoa (2, 3, 4). [0004] So far, nifurtimox has only been described to have efficacy against protozoan species of the genus Trypanosoma, such as Trypanosoma brucei and Trypanosoma cruzi (5). Trypanosomes have flagella that originate from a basal body ("tricola basal body"), to which they attach to produce a corrugated membrane....

AI Technical Summary

Problems solved by technology

[0013] Many of these types of active substances have been used to treat giardiasis for a long time, and for most resistance can be detected and proven to lead to treatment failure

Images